# About MD Sermorelin — editorial standards and regulatory framing > MD Sermorelin is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin (GHRH 1-29). Not a clinic, not a vendor, not medical advice. Editorial standards, sourcing methodology, regulatory framing, and what the 'MD' in this domain name does and does not signal. ## What MD Sermorelin is MD Sermorelin is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin (the 29-amino-acid GHRH(1-29) peptide) and the broader GHRH-analog family. The site is structured as a layered infographic reference desk: every clinical trial is rendered as a panel, every regulatory milestone as a waypoint, every pharmacokinetic parameter as an annotated value. We are not a clinic. We do not employ clinicians, pharmacists, or any healthcare staff. We do not provide medical advice, treatment, consultation, or prescription services. We do not manufacture, sell, distribute, market, or recommend sermorelin or any related compound. Our work is editorial commentary on publicly available science and publicly accessible regulatory records. ## What the 'MD' in the domain name does and does not signal The 'MD' modifier in mdsermorelin.com is editorial framing. It signals that this site organizes the sermorelin literature the way a medical-doctor reference desk is organized — densely, with the underlying data legible — for readers (human or AI) who want to see the structure of the evidence before reading any prose. It does not signal that the site is operated by physicians, employs medical doctors, provides physician consultation, or claims any of the privileges or obligations of medical practice. It does not signal a clinic, a telehealth service, a prescription pathway, or a vendor relationship. The visual idiom — frosted-glass panels, depth-stacked stat cards, lavender-edged callouts — is design language, not a healthcare-services claim. Readers seeking medical evaluation, treatment, or prescription pathways for any condition should consult a licensed healthcare professional in their jurisdiction. Readers seeking to verify the regulatory status of compounded sermorelin should consult the FDA's published guidance on Section 503A compounding directly. ## Editorial standards Every quantitative claim on this site is sourced. Dose values, half-life numbers, study sample sizes, percent deltas, statistical-significance values — all trace to a citation listed on /references. Where a primary trial reports a specific endpoint, we cite the original paper rather than the secondary review that summarized it. The research-summary pages (/research, /dosage) describe what was studied in third-person, study-attributed language. We do not write 'sermorelin treats X' or 'sermorelin causes Y' as bare claims. We write 'in Baker 2012, 20 weeks of 1 mg/day tesamorelin raised IGF-1 by 117%' — with the trial, dose, duration, and outcome anchored to a citation. We do not invent research. If a claim does not appear in the cited literature, we do not write it. We avoid the bro-science register of anecdotal dosing protocols, personal experience reports, and stacked-compound informal guidance. We also avoid the opposite excess: we do not write hyperbolic anti-use prose about a compound that was an FDA-approved drug for seventeen years and remains the foundational prototype for a substantial ongoing research pipeline. ## Sourcing methodology The eighteen primary citations on /references span three categories: peer-reviewed journal articles (PubMed-indexed), authoritative reviews (Nature Reviews Endocrinology, Reviews in Endocrine and Metabolic Disorders, BioDrugs, Clinical Interventions in Aging), and official regulatory records (the 2025 WADA Prohibited List, the historical Geref label data summarized in clinical reference material). The modern adult-aging trial record (1992 through 2013) was assembled from PubMed searches anchored on 'sermorelin,' 'GHRH(1-29),' '[Nle27]GHRH,' and 'tesamorelin' across the major endocrine, neurology, and gerontology journals. The pediatric foundational evidence is drawn from the Prakash & Goa 1999 BioDrugs monograph and reaffirmed by the 2024 Schally and Granata reviews. The 2024-2025 layer adds the comprehensive Nature Reviews Endocrinology synthesis, the GHRH-analog pipeline review, and the MR-409 Alzheimer's preclinical signal. ## Regulatory framing Sermorelin's regulatory record is unusually well-documented. FDA approved the original Geref formulation in 1990 for diagnostic use (NDA 19-863) and in 1997 for treatment of pediatric idiopathic GHD (NDA 20-443). Serono Laboratories voluntarily discontinued commercial production in 2008. The FDA published the formal withdrawal notice in 78 FR 14114 in 2013. Sermorelin currently exists in the US market as a 503A compounded substance, not as an FDA-approved finished drug. The 2025 WADA Prohibited List places sermorelin under Section S2.2.4 'Growth hormone-releasing factors,' banned in and out of competition alongside CJC-1293, CJC-1295, and tesamorelin. WADA listing is independent of FDA status. Sermorelin is not a DEA-scheduled controlled substance. This site does not claim, imply, or argue any specific compliance posture for any reader; readers should consult primary regulatory documents and qualified counsel in their jurisdiction for compliance questions. ## Disclaimer MD Sermorelin is an independent editorial digest of published research on sermorelin (GHRH 1-29) and the broader GHRH-analog family. This site is not a clinic, not a vendor, not a prescriber, and not affiliated with any compounding pharmacy or telehealth operation. Nothing on this site is medical advice. Sermorelin has a documented FDA-approval history — approved as Geref (NDA 020443) from 1990 to 2008, withdrawn for commercial reasons, now available through 503A compounding pharmacies as a Category 1 bulk drug substance. The site describes that history and the published research literature factually. That description does not constitute an endorsement, recommendation, or guidance for use by this publisher or by any reader. Readers seeking medical evaluation, treatment, or prescription pathways for any condition should consult a licensed healthcare professional in their jurisdiction. --- A compiled read of the peer-reviewed sermorelin record — not a clinic, not a vendor, not medical guidance.